Recent medical research highlights advancements in chronic disease treatment, risks in geriatric prescribing, and evolving patient care challenges.

The 2026 ADA Scientific Sessions featured a significant debate regarding muscle mass loss during GLP-1 therapy, emphasizing the need for clinician counseling to mitigate risks.

Clinicians are navigating a surge in patient inquiries and usage of the unapproved weight-loss drug retatrutide, largely fueled by social media trends.

A study on obese mice indicates that whole-plant cannabis extracts are more effective at improving glucose control than THC alone, suggesting potential avenues for future metabolic research.

Researchers are evaluating tavapadon as a potential new dopamine agonist for Parkinson's disease, which could mark the first new pharmacological treatment in this class in decades.

Experts have warned that inappropriate prescribing cascades in older adults, where side effects of one drug lead to unnecessary new prescriptions, are creating significant health risks.

Clinical trial results for inoperable non-small cell lung cancer (NSCLC) show that adding atezolizumab to stereotactic body radiotherapy (SBRT) increases toxicity without providing a survival benefit.

A narrative review suggests a U-shaped correlation between testosterone levels and atrial fibrillation risk, indicating that both high and low levels may pose health dangers for men.

Changing climate patterns are causing an earlier start to the pollen season, shifting the timeline for allergy symptom onset and increasing the demand for early patient care.